guest ::
| Home > Publications database > Transient reduction of spontaneous neuronal network activity by sublethal amyloid ß (1-42) peptide concentrations > print |
| Home > Publications database > Transient reduction of spontaneous neuronal network activity by sublethal amyloid ß (1-42) peptide concentrations > print |
| 001 | 3798 | ||
| 005 | 20200402205552.0 | ||
| 024 | 7 | _ | |2 pmid |a pmid:19214376 |
| 024 | 7 | _ | |2 DOI |a 10.1007/s00702-009-0188-y |
| 024 | 7 | _ | |2 WOS |a WOS:000263897900011 |
| 037 | _ | _ | |a PreJuSER-3798 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 084 | _ | _ | |2 WoS |a Clinical Neurology |
| 084 | _ | _ | |2 WoS |a Neurosciences |
| 100 | 1 | _ | |a Görtz, P. |b 0 |0 P:(DE-HGF)0 |
| 245 | _ | _ | |a Transient reduction of spontaneous neuronal network activity by sublethal amyloid ß (1-42) peptide concentrations |
| 260 | _ | _ | |a Wien [u.a.] |b Springer |c 2009 |
| 300 | _ | _ | |a 351 - 355 |
| 336 | 7 | _ | |a Journal Article |0 PUB:(DE-HGF)16 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 440 | _ | 0 | |a Journal of Neural Transmission |x 0936-3076 |0 17861 |y 3 |v 116 |
| 500 | _ | _ | |a This study was supported by a grant from the Stiftung fur Altersforschung (Age Research Foundation) of the Heinrich-Heine-Universitat Dusseldorf (C. L.-A. and P. G.). |
| 520 | _ | _ | |a Soluble amyloid beta(1-42) (A beta(1-42)) peptide has recently been assigned a key role in early Alzheimer's disease (AD) pathophysiology accounting for synaptic dysfunction before amyloid plaque formation and neurodegeneration can occur. Following sublethal A beta(1-42) administration, we observed an acute but transient reduction of the spike and burst rate of spontaneously active cortical networks cultured on microelectrode arrays. This simple experimental system appears suitable for future long-term pharmacological and genetic studies of A beta(1-42) signaling, thus providing a valuable new tool in AD research. |
| 536 | _ | _ | |a Funktion und Dysfunktion des Nervensystems |c P33 |2 G:(DE-HGF) |0 G:(DE-Juel1)FUEK409 |x 0 |
| 588 | _ | _ | |a Dataset connected to Web of Science, Pubmed |
| 650 | _ | 2 | |2 MeSH |a Action Potentials: drug effects |
| 650 | _ | 2 | |2 MeSH |a Action Potentials: physiology |
| 650 | _ | 2 | |2 MeSH |a Amyloid beta-Peptides: administration & dosage |
| 650 | _ | 2 | |2 MeSH |a Amyloid beta-Peptides: metabolism |
| 650 | _ | 2 | |2 MeSH |a Amyloid beta-Peptides: pharmacology |
| 650 | _ | 2 | |2 MeSH |a Animals |
| 650 | _ | 2 | |2 MeSH |a Cell Culture Techniques |
| 650 | _ | 2 | |2 MeSH |a Cerebral Cortex: cytology |
| 650 | _ | 2 | |2 MeSH |a Electrophysiology |
| 650 | _ | 2 | |2 MeSH |a Microelectrodes |
| 650 | _ | 2 | |2 MeSH |a Nerve Net: drug effects |
| 650 | _ | 2 | |2 MeSH |a Nerve Net: physiology |
| 650 | _ | 2 | |2 MeSH |a Neurons: drug effects |
| 650 | _ | 2 | |2 MeSH |a Neurons: physiology |
| 650 | _ | 2 | |2 MeSH |a Peptide Fragments: administration & dosage |
| 650 | _ | 2 | |2 MeSH |a Peptide Fragments: metabolism |
| 650 | _ | 2 | |2 MeSH |a Peptide Fragments: pharmacology |
| 650 | _ | 2 | |2 MeSH |a Rats |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Amyloid beta-Peptides |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a Peptide Fragments |
| 650 | _ | 7 | |0 0 |2 NLM Chemicals |a amyloid beta-protein (1-42) |
| 650 | _ | 7 | |a J |2 WoSType |
| 653 | 2 | 0 | |2 Author |a Alzheimer's disease |
| 653 | 2 | 0 | |2 Author |a A beta(1-42) |
| 653 | 2 | 0 | |2 Author |a Cortical neurons |
| 653 | 2 | 0 | |2 Author |a Neuronal network activity |
| 653 | 2 | 0 | |2 Author |a Microelectrode array |
| 700 | 1 | _ | |a Opatz, J. |b 1 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Siebler, M. |b 2 |0 P:(DE-HGF)0 |
| 700 | 1 | _ | |a Funke, S. A. |b 3 |u FZJ |0 P:(DE-Juel1)VDB65869 |
| 700 | 1 | _ | |a Willbold, D. |b 4 |u FZJ |0 P:(DE-Juel1)132029 |
| 700 | 1 | _ | |a Lange-Asschenfeldt, C. |b 5 |0 P:(DE-HGF)0 |
| 773 | _ | _ | |a 10.1007/s00702-009-0188-y |g Vol. 116, p. 351 - 355 |p 351 - 355 |q 116<351 - 355 |0 PERI:(DE-600)2591260-4 |t Journal of neural transmission / Parkinson's disease and dementia section |v 116 |y 2009 |x 0936-3076 |
| 856 | 7 | _ | |u http://dx.doi.org/10.1007/s00702-009-0188-y |
| 909 | C | O | |o oai:juser.fz-juelich.de:3798 |p VDB |
| 913 | 1 | _ | |k P33 |v Funktion und Dysfunktion des Nervensystems |l Funktion und Dysfunktion des Nervensystems |b Gesundheit |0 G:(DE-Juel1)FUEK409 |x 0 |
| 914 | 1 | _ | |y 2009 |
| 915 | _ | _ | |0 StatID:(DE-HGF)0010 |a JCR/ISI refereed |
| 920 | 1 | _ | |d 31.12.2010 |g ISB |k ISB-3 |l Strukturbiochemie |0 I:(DE-Juel1)VDB942 |x 0 |
| 920 | 1 | _ | |0 I:(DE-82)080012_20140620 |k JARA-HPC |l Jülich Aachen Research Alliance - High-Performance Computing |g JARA |x 1 |
| 970 | _ | _ | |a VDB:(DE-Juel1)110188 |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a ConvertedRecord |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 980 | _ | _ | |a I:(DE-82)080012_20140620 |
| 980 | _ | _ | |a UNRESTRICTED |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| 981 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 981 | _ | _ | |a I:(DE-Juel1)VDB1346 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|